Development of efficacious combination therapies with RNA Polymerase I inhibitors
This study aims to develop effective combination therapies using RNA Polymerase I (Pol I) inhibitors to enhance therapeutic efficacy and combat resistance in cancer treatment through synergistic effects with other drugs or treatments.
Research themes
Project status
Content navigation
About
This study focuses on developing effective combination therapies involving RNA Polymerase I (Pol I) inhibitors. By exploring synergistic effects with other drugs or treatments, the research aims to enhance therapeutic efficacy and potentially overcome resistance in cancer treatment.
Members
Supervisor
Senior Fellow
Lead, ANU Centre for Therapeutic Discovery (ACTD)
Platform Manager, National Therapeutic mRNA Platform
Associate Professor in Pharmacogenomic Technologies
Group Leader
Group Leader
Deputy Dean, Research, CHM
NHMRC Principle Res. Fellow